An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris



Status:Completed
Conditions:Acne, Acne, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:9 - 11
Updated:2/13/2019
Start Date:October 28, 2016
End Date:March 21, 2018

Use our guide to learn which trials are right for you!

An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <12 Years of Age With Acne Vulgaris

This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression
potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve
hours for two weeks, in pediatric patients 9 to less than 12 years of age with acne vulgaris.
Adrenal suppression effects and systemic safety are an important safety concern. The current
study is designed to investigate these potential concerns under maximal use conditions.


Inclusion Criteria:

- Patient must provide written informed assent and be accompanied by the parent or legal
guardian at the time of assent/consent signing. The parent or legal guardian must
provide written informed consent for the patient.

- Patient has moderate to severe facial acne vulgaris as determined by the Investigator
and obvious acne on the trunk (i.e., shoulders, upper chest, and/or back).

- Females of childbearing potential must be using highly effective birth control methods
with a negative urine pregnancy test (UPT) at study start.

- Patient must be in general good health with normal renal function and no clinically
relevant abnormalities present at study start.

- Patient and parent/guardian are able to communicate with the staff and are willing to
comply with study instructions, reside at and/or return to the clinic for required
visits.

Exclusion Criteria:

- Patient is pregnant, lactating, or is planning to become pregnant during the study.

- Patient has a Body Mass Index (BMI) for age percentile > 95%.

- Patient has any skin or medical condition, including facial hair that could interfere
with the evaluation of the test article or requires the use of interfering topical or
systemic therapy.

- Patient has received an investigational drug or been treated with an investigational
device within 30 days prior to study start.

- Patient is currently enrolled in an investigational drug or device study.

- Patient has any condition which, in the investigator's opinion, would make it unsafe
for the patient to participate in this research study.

- Patient has known allergy or sensitivity to CB-03-01 or any of its ingredients

- Patient has participated in a previous CB-03-01 study.
We found this trial at
4
sites
?
mi
from
Fort Smith, AR
Click here to add this to my saved trials
?
mi
from
Czestochowa,
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials